
July 2 (Reuters) - Bio-Thera Solutions Ltd 688177.SS:
IDMC PROVIDES POSITIVE RECOMMENDATION FOR BIO-THERA SOLUTION'S BAT4406F (ADCC-ENHANCED ANTI-CD20 MAB) IN NEUROMYELITIS OPTICA SPECTRUM DISORDER BASED ON INTERIM ANALYSIS OF PIVOTAL PHASE II/III TRIAL
BIO-THERA SOLUTIONS LTD - TO CLOSE PATIENT ENROLLMENT AHEAD OF SCHEDULE
BIO-THERA SOLUTIONS LTD - IDMC RECOMMENDS EARLY TERMINATION OF BAT4406F TRIAL DUE TO EFFICACY
BIO-THERA SOLUTIONS LTD - TO FILE FOR REGULATORY APPROVAL FROM NMPA
BIO-THERA SOLUTIONS LTD - TO EXPLORE BAT4406F IN OTHER INDICATIONS